- Home
- IAUX vs LBRX Comparison
IAUX vs LBRX Comparison
Compare IAUX & LBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IAUX | LBRX |
|---|---|---|
| Founded | 2020 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | 2021 | 2025 |
Fundamental Metrics
Financial Performance| Metric | IAUX | LBRX |
|---|---|---|
| Price | $1.49 | $44.89 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 11 |
| Target Price | $3.22 | ★ $58.00 |
| AVG Volume (30 Days) | ★ 7.0M | 372.4K |
| Earning Date | 11-02-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 11.76 | ★ 98.22 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $95,193,000.00 | N/A |
| Revenue This Year | $89.94 | N/A |
| Revenue Next Year | $39.11 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 89.12 | N/A |
| 52 Week Low | $0.93 | $14.32 |
| 52 Week High | $2.24 | $50.16 |
Technical Indicators
Market Signals| Indicator | IAUX | LBRX |
|---|---|---|
| Relative Strength Index (RSI) | 49.61 | 64.68 |
| Support Level | $1.41 | $27.40 |
| Resistance Level | $1.54 | $49.74 |
| Average True Range (ATR) | 0.07 | 2.77 |
| MACD | 0.00 | 0.61 |
| Stochastic Oscillator | 78.00 | 90.82 |
Price Performance
Historical ComparisonAbout IAUX i-80 Gold Corp.
i-80 Gold Corp is a well-financed gold and silver producer engaged in the exploration, development, and production of gold, silver, and poly-metallic deposits. The Company's principal assets include the Ruby Hill Mine, Lone Tree Mine, Granite Creek Mine, and McCoy-Cove Project.
About LBRX LB Pharmaceuticals Inc
LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.